A clinical trial to look at the safety and effectiveness of three different combinations of drugs for treating follicular lymphoma, mosunetuzumab plus lenalidomide, glofitamab plus lenalidomide, or glofitamab plus obinutuzumab and lenalidomide,
![JCI - Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor JCI - Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor](https://dm5migu4zj3pb.cloudfront.net/manuscripts/25000/25342/medium/JCI0525342.f9.jpg)
JCI - Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor
A clinical trial to look at the safety and effectiveness of three different combinations of drugs for treating follicular lymphoma, mosunetuzumab plus lenalidomide, glofitamab plus lenalidomide, or glofitamab plus obinutuzumab and lenalidomide,
![Detection and characterization of olmutinib reactive metabolites by LC–MS/MS: Elucidation of bioactivation pathways - Attwa - 2020 - Journal of Separation Science - Wiley Online Library Detection and characterization of olmutinib reactive metabolites by LC–MS/MS: Elucidation of bioactivation pathways - Attwa - 2020 - Journal of Separation Science - Wiley Online Library](https://analyticalsciencejournals.onlinelibrary.wiley.com/cms/asset/39189fe2-d76b-4eb0-a56c-566887c082ce/jssc.v43.4.cover.jpg)